구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | PLD (Pegylated liposomal doxorubicin, Pegylated liposomal doxorubicin (PLD)) AGO Research GmbH·Ovarian Neoplasms 177 trials·t½ 3 h |
|---|---|
Overview Program | Pegylated liposomal doxorubicin (PLD) |
Overview Company | AGO Research GmbH |
Overview Modality | ANTIBODY |
Overview Target | Ovarian Neoplasms |
Overview Indication | Ovarian Neoplasms; Fallopian Tube Neoplasms |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | target of HMB action and demonstrate that HMB preserves muscle homeostasis through coordinated modulation of anabolic signaling |
MoA Biomarker | biomarkers (blood eosinophil levels and lung function) |
PK/PD Half-life | 3 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | A novel quantification method for unencapsulated doxorubicin in tissues: unlocking PK/PD and TK/TD insights for pegylated liposomal doxorubicin.. Pegylated liposomal doxorubicin (PLD) is the first FDA-approved liposomal product in the oncology field and has been extensively investigated over the years. Although PLD has been extensively studied, measurement of unencapsulated doxorubicin i… |
Clinical Safety signal | A novel quantification method for unencapsulated doxorubicin in tissues: unlocking PK/PD and TK/TD insights for pegylated liposomal doxorubicin.. Pegylated liposomal doxorubicin (PLD) is the first FDA-approved liposomal product in the oncology field and has been extensively investigated over the years. Although PLD has been extensively studied, measurement of unencapsulated doxorubicin i… |
Clinical Reported PFS | 8.2 |
Clinical Reported OS | 14.9 |
Clinical Result source | ClinicalTrials.gov NCT03164980 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03164980 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | PLD (Pegylated liposomal doxorubicin, Pegylated liposomal doxorubicin (PLD)) AGO Research GmbH·Ovarian Neoplasms 177 trials·t½ 3 h |
|---|---|
Overview Program | Pegylated liposomal doxorubicin (PLD) |
Overview Company | AGO Research GmbH |
Overview Modality | ANTIBODY |
Overview Target | Ovarian Neoplasms |
Overview Indication | Ovarian Neoplasms; Fallopian Tube Neoplasms |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | target of HMB action and demonstrate that HMB preserves muscle homeostasis through coordinated modulation of anabolic signaling |
MoA Biomarker | biomarkers (blood eosinophil levels and lung function) |
PK/PD Half-life | 3 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | A novel quantification method for unencapsulated doxorubicin in tissues: unlocking PK/PD and TK/TD insights for pegylated liposomal doxorubicin.. Pegylated liposomal doxorubicin (PLD) is the first FDA-approved liposomal product in the oncology field and has been extensively investigated over the years. Although PLD has been extensively studied, measurement of unencapsulated doxorubicin i… |
Clinical Safety signal | A novel quantification method for unencapsulated doxorubicin in tissues: unlocking PK/PD and TK/TD insights for pegylated liposomal doxorubicin.. Pegylated liposomal doxorubicin (PLD) is the first FDA-approved liposomal product in the oncology field and has been extensively investigated over the years. Although PLD has been extensively studied, measurement of unencapsulated doxorubicin i… |
Clinical Reported PFS | 8.2 |
Clinical Reported OS | 14.9 |
Clinical Result source | ClinicalTrials.gov NCT03164980 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03164980 |
추천 비교
추천 비교